Is Geron Stock a Buy Following Its First New Drug Approval?
Shares of (NASDAQ: GERN) finished the week ended June 7 about 32% higher. The market was reacting to news the company's investors had been waiting to hear for decades.
On June 6, the U.S. Food and Drug Administration (FDA) approved Geron's first drug, imetelstat (brand name Rytelo), to treat a rare form of cancer.
Rytelo is a new treatment for an underserved population. That's generally a recipe for success in the biotechnology industry, but independent companies launching their first commercial product tend to miss expectations.
Source Fool.com
Geron Corp. Aktie
4,05 €
1,89 %
Eine klare Neigung zu Buy-Einschätzungen bei Geron Corp., ohne Sell-Einschätzungen.
Bei einem Kursziel von 5 € ergibt sich ein positives Potenzial von 23.37% für Geron Corp. im Vergleich zum aktuellen Kurs von 4.05 €.
